A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma
研究单位：[1]Antengene Corporation[2]Anhui Provincial Cancer Hospital,Hefei,Anhui,China,230031[3]Beijing Tongren Hospital.CMU,Beijing,China,100005[4]Peking University Third Hospital,Beijing,China,100191[5]Chongqing University Cancer Hospital,Chongqing,Chongqing,China,400030[6]Sun Yat-sen University Cancer Center,Guangzhou,Guangdong,China,510060[7]Guangxi Medical University Cancer Hospital,Nanning,Guangxi,China,530021[8]Henan Cancer Hospital,Zhengzhou,Henan,China,450008[9]Hubei Cancer Hospital,Wuhan,Hubei,China,430079[10]Jiangsu Cancer Hospital,Nanjing,Jiangsu,China,210000[11]Jiangsu Province Hospital,Nanjing,Jiangsu,China,210029[12]Jilin Cancer Hospital,Changchun,Jilin,China[13]Fudan University Shanghai Cancer Center,Shanghai,Shanghai,China,200032[14]Tianjin Medical Universisity Cancer Institute & Hospital,Tianjin,China,300060[15]The First Affiliated Hospital, Zhejiang University School of Medicine,Hangzhou,Zhejiang,China,310003
研究目的：
This trial is proposed with treatment of ATG-010 combined with chemotherapy regimens which will be chosen by investigators (ICE [ifosfamide+carboplatin+etoposide] or GEMOX [gemcitabine+oxaliplatin] or Tislelizumab), after treatments of 2 to 6 cycles transferring to ATG-010 monotherapy maintenance treatment, to evaluate the safety, tolerability, and primary efficacy of ATG-010 in R/R PTCL and NK/T-cell lymphoma patients.
